• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic wins CE Mark for MiniMed 670G hybrid closed-loop insulin system

June 25, 2018 By Brad Perriello

Medtronic MiniMed 670GMedtronic (NYSE:MDT) said today that it won CE Mark approval in the European Union for its MiniMed 670G hybrid closed-loop insulin management system for Type I diabetes patients age 7 and older.

Fridley, Minn.-based Medtronic said it has clinical programs under way to back expanded indications for the device, which is designed to continuously monitor regulate basal insulin delivery using the company’s SmartGuard algorithm and Guardian Sensor 3. The MiniMed 670G also uses Ascensia Diabetes Care‘s ContourNext Link 2.4 blood glucose monitor. The aim is to keep diabetic patients in the optimal glycemic range of 70-180 mg/dL or 3.9-10 mmol/L.

Medtronic said it plans to have MiniMed 670G on the market in “select” European countries in the autumn of 2018.

“We’re proud to introduce our most advanced SmartGuard Auto Mode algorithm outside of the United States, which not only helps to prevent lows but works to drive time in range – a most important measure of the effect of diabetes management on a patient’s glucose levels – by decreasing time in hyperglycemia,” advanced insulin management president Alejandro Galindo said in prepared remarks. “The MiniMed 670G system advances our ability to automatically suspend and resume insulin delivery to the next level by automating self-adjusting basal insulin delivery every 5 minutes based on sensor glucose values – providing the most advanced algorithm available to deliver leading clinical outcomes.”

“We have seen that this innovation offers great promise for better glucose control and improved quality of life for those living with Type 1 diabetes,” added Dr. Pratik Choudhary of King’s College London. “The ability of the MiniMed 670G system to stabilize glucose levels automatically is an important advancement, and I look forward to introducing it to my patients in Europe.”

Filed Under: Diabetes, Featured, Regulatory/Compliance Tagged With: Ascensia Diabetes Care, Medtronic

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS